Vol. 8, Issue 8 (2019)

The aim of the study was to assess the feasibility of using copeptin and NT-proBNP in the patients with decompensated heart failure in the early and late post-infarction periods and to determine changes in their correlation during the rehabilitation process.

Materials and Methods: There were examined 120 patients with Q-QS wave and non-Q wave myocardial infarction, stage II A-B decompensated chronic heart failure according to the classification proposed by Vasylenko V.Kh. and Strazhesko M.D., the New York Heart Association functional class III-IV.

Studygroupswerehomogenous by age, gender, disease severity, duration of the post-infarction period, clinical signs of decompensation, that served as a basis for inclusion of the patients in the study.

All the patients underwent the six-minute walk test in a quiet 30-50-m long hospital corridorin the morning. In all the patients, serum concentration of N-terminal pro-brain natriuretic peptide (pg/mg) was determined using commercial ELISA kit forHumanN-terminal pro-brain natriuretic peptide (Biomedica, Slovakia S.R.O.). The results obtained were statistically processed on the personal computer by means of an advanced analytics software package STATISTICA-7 and a statistical software package “Microsoft-Excel” using the statistical variation analysis. During 2 months of treatment, plasma copeptin levels decreased in all the study groups.

Results and Discussion: When studying a dynamic of changes in blood level of N-terminal pro-brain natriuretic peptide, there was observed its significant reduction in all the groups after treatment. The combined use of succinic acid and arginine preparations when treating the patients with Q wave and non-Q wave myocardial infarction and decompensated heart failure allowed us to reduce blood levels of N-terminal pro-brain natriuretic peptide by 41.03% and 41.61% 2 months after the beginning of treatment. The combined use of succinic acid and arginine preparations in combination therapy for decompensated heart failure allowed us to reduce blood levels of N-terminal pro-brain natriuretic peptide under conditions of graded exercises. Thus, during treatment of the patients of all the study groups, there was observed a gradual reduction in the concentration of N-terminal pro-brain natriuretic peptide in the blood both at rest and during graded exercises.

Conclusions: Copeptin and N-terminal pro-brain natriuretic peptide levels can be used both for the prediction of heart failure in the post-infarction period and quality assessment of treatment performed.